Regeneron Pharmaceuticals

Plasma-free VEGF level decreases with aflibercept, bevacizumabCompared with intravitreous ranibizumab, the decreases in the plasma-free VEGF levels were greater with intravitreous aflibercept and bevacizumab in patients with diabetic macular edema.
Aflibercept shows macular perfusion gains in VISTA subanalysisThe use of aflibercept led to greater improvement in macular perfusion status in a phase III trial with DME patients. Those with baseline nonperfusion tended to have more advanced disease.
Ultra-widefield angiography: New window for retinovascular featuresQuantitative assessment of retinovascular features on ultra-widefield angiography images showed significant improvements in leakage and ischemia following treatment with aflibercept in patients with diabetic macular edema and retinal vein occlusion.
Outcomes differ from trials with ‘real-world’ anti-VEGF therapy for DMEThe visual outcomes after anti-VEGF therapy administered to treat diabetic macular edema in the “real world” do not achieve those reported in randomized clinical trials. Eyes with better baseline visual acuity are disproportionately affected.
Anti-angiogenic agent, platform planned for human trialFindings from preclinical studies show that a novel intravitreal depot of an anti-angiogenic drug releases the medication over a period of at least 6 months, is well-tolerated, and prevents VEGF-induced retinal vascular leakage.
Anti-VEGF drugs: Safe and effective for treating DMEData from large randomized trials indicate that diabetic macular edema can be treated safely and effectively with anti-vascular endothelial growth factor therapies.
HHS, drugmaker partner on Ebola drugThe U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and Regeneron Pharmaceuticals in Tarrytown, New York, are partnering to develop a novel Ebola virus treatment.
Rescue alfibercept treatment proves successful for patients with BRVOPatients with branch retinal vein occlusion had better visual outcomes and decreased macular edema following intravitreal injection of aflibercept compared with laser treatment.
Tanezumab clinical trials to resumePfizer and Eli Lilly and Company said they will resume Phase 3 clinical studies for tanezumab for chronic pain, after the Food and Drug Administration (FDA) lifted a partial hold on trials.
FDA drug approvals December 2014